Moderna (MRNA) Current Deferred Revenue (2017 - 2026)

Moderna (MRNA) has reported Current Deferred Revenue for 10 consecutive years, with $442.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Deferred Revenue rose 56.18% year-over-year to $442.0 million in Q2 2026; TTM through Jun 2026 was $442.0 million, a 56.18% increase from a year earlier, with the FY2025 full-year figure at $252.0 million, up 19.43% from the prior year.
• Current Deferred Revenue was $442.0 million for Q2 2026 at Moderna, up from $256.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $6.1 billion in Q1 2022 and troughed at $183.0 million in Q1 2025.
• A 5-year average of $1.5 billion and a median of $634.0 million in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue slumped 75.99% in 2023 and jumped 56.18% in 2026, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $2.7 billion in 2022, then plunged by 75.99% to $651.0 million in 2023, then sank by 67.59% to $211.0 million in 2024, then rose by 19.43% to $252.0 million in 2025, then soared by 75.4% to $442.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $442.0 million (Q2 2026), $256.0 million (Q1 2026), and $252.0 million (Q4 2025), per Business Quant data.